Neeta Pandit-Taskar
Overview
Explore the profile of Neeta Pandit-Taskar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
161
Citations
3343
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Souweidane M, Bander E, Zanzonico P, Reiner A, Manino N, Haque S, et al.
Neuro Oncol
. 2025 Feb;
PMID: 39969230
Background: Median survival for patients with Diffuse Intrinsic Pontine Glioma (DIPG) is 8-12 months. Methods: A phase 1, open label, 3 + 3 dose escalation trial delivered radiolabeled 124I-Omburtamab, targeting...
2.
Yusufaly T, Roncali E, Brosch-Lenz J, Uribe C, Jha A, Currie G, et al.
J Nucl Med
. 2025 Feb;
PMID: 39947910
Radiopharmaceutical therapy (RPT), with its targeted delivery of cytotoxic ionizing radiation, demonstrates significant potential for treating a wide spectrum of malignancies, with particularly unique benefits for metastatic disease. There is...
3.
Strigari L, Schwarz J, Bradshaw T, Brosch-Lenz J, Currie G, El-Fakhri G, et al.
J Nucl Med
. 2025 Jan;
PMID: 39848769
Computational nuclear oncology for precision radiopharmaceutical therapy (RPT) is a new frontier for theranostic treatment personalization. A key strategy relies on the possibility to incorporate clinical, biomarker, image-based, and dosimetric...
4.
McGale J, Khurana S, Howell H, Nakhla A, Roa T, Doshi P, et al.
Clin Nucl Med
. 2025 Jan;
50(3):e138-e145.
PMID: 39780367
Breast cancer presents a significant global health challenge, necessitating continued innovation in diagnostic and therapeutic approaches. Recent advances have led to the identification of cancer-associated fibroblasts, which are highly prevalent...
5.
Pandit-Taskar N, Basu E, Balquin E, Mozley P, Jacobson A, Modak S
Nucl Med Commun
. 2024 Dec;
46(3):245-247.
PMID: 39641193
Objective: Limited safety data have been published on fluorine-18 ( 18 F) meta-fluorobenzylguanidine ( m FBG), a new PET radiopharmaceutical for imaging neural crest and neuroendocrine tumors. As part of...
6.
Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Abboud C, et al.
J Clin Oncol
. 2024 Sep;
43(2):201-213.
PMID: 39298738
Purpose: Older patients with relapsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transplantation (alloHCT). SIERRA compared a targeted pretransplant regimen involving the anti-CD45 radioconjugate I-apamistamab...
7.
Shuch B, Pantuck A, Bernhard J, Morris M, Master V, Scott A, et al.
Lancet Oncol
. 2024 Sep;
25(10):1277-1287.
PMID: 39270701
Background: With limitations of conventional imaging and biopsy, accurate, non-invasive techniques to detect clear-cell renal cell carcinoma in patients with renal masses remain an unmet need. Zr-labelled monoclonal antibody ([Zr]Zr-girentuximab)...
8.
Kuo P, Covington M, Lee D, Wong T, Pandit-Taskar N
J Nucl Med Technol
. 2024 Sep;
52(3):208-211.
PMID: 39237335
Although guidelines for the use of Lu-PSMA-617 published by various organizations are important, they do not include all the essential, practical points necessary for a complete institutional protocol. Therefore, a...
9.
Farouk Sait S, Kernan N, Klein E, Spitzer B, Fein Levy C, Fish J, et al.
Pediatr Blood Cancer
. 2024 Sep;
71(11):e31297.
PMID: 39217426
Background: The prognosis for patients with central nervous system (CNS) retinoblastoma (RB) (trilateral or stage 4b metastatic RB) treated with high-dose chemotherapy and autologous stem cell transplant (HDC-ASCT) remains poor....
10.
Nanni C, Castellucci P, Fanti S, Pandit-Taskar N
PET Clin
. 2024 Aug;
19(4):xiii-xiv.
PMID: 39214639
No abstract available.